Can CME Group (CME) Justify A Full Price After Record Volumes?

CME Group stock has delivered a strong 82.6% gain over the past 5 years, yet the current checks suggest the shares are not a clear bargain, with the Excess Returns intrinsic value estimate sitting close to the market price while traditional multiples lean expensive. Recent trading milestones and product launches help explain the interest in CME Group, but they also raise the question of how much of that strength is already reflected in the valuation.

• Over 5 years, CME Group has returned 82.6%, which puts the current share price in a very different context compared with where longer term holders came in.
• Record open interest in Henry Hub natural gas futures and strong activity across U.S. Treasury and metals contracts can support expectations for CME Group's future cash generation, but competition from newer venues and event or weather focused trading platforms may limit how much investors are willing to pay for that growth.
• The broader valuation checks, with a low value score of 2 out of 6, point to CME Group stock leaning expensive rather than offering clear wide margin value.

The stock's next move may depend on whether recent volume and product news can justify CME Group trading at a premium to its intrinsic value estimate.

Scan CME Group's recent volumes, then size up other derivatives exchanges and brokers by screening for solid balance sheet and fundamentals stocks screener (52 results). This may help identify firms that handle volatility with more resilient financial footing.

Where Does CME Group Sit on Excess Returns?

The Excess Returns model looks at how efficiently CME Group turns its equity base into profits above its cost of capital. For CME Group, book value sits at $73.82 per share and the stable earnings power used in the model is $14.13 per share, based on forward-looking analyst estimates for return on equity. With an average return on equity of 16.78% and a cost of equity of $6.70 per share, the model attributes $7.43 per share to excess return over the required rate.

When those excess returns are projected onto a stable book value of $84.22 per share, the model arrives at an intrinsic value of $258.83 per share. That is slightly below the current market price, which implies the stock screens about 8.7% overvalued in this framework. CME Group’s recent records in natural gas and U.S. Treasury contracts help explain why investors appear comfortable paying a premium over what the Excess Returns model supports.

On this intrinsic value view, CME Group stock currently looks roughly fairly valued with a modest tilt toward overvalued.

CME Group is fairly valued according to our Excess Returns, but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for CME Group.

Has CME Group Run Too Far on Earnings?

P/E is a useful lens for CME Group because earnings are a key output of its fee based trading and clearing model. Right now CME Group trades on a P/E of 23.7x, which is lower than the wider Capital Markets industry average of 39.7x and also below the peer average of 26.8x. On raw comparison, that leaves CME Group on a discount to much of the sector.

The tailored fair P/E ratio for CME Group is 15.7x, which reflects what investors might typically pay given its margins, size and risk profile. Against that fair level, the current 23.7x P/E is higher by a wide margin, which points to investors already paying up for CME Group’s franchise and product set, including the recent futures and options launches. This gap suggests the market is ascribing a premium that is not fully supported by this earnings based yardstick.

On the P/E multiple, CME Group stock currently screens as overvalued.

See what the numbers say about this price — find out in our valuation breakdown.

The CME Group Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where this CME Group valuation puzzle leaves off. They spell out which combinations of future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today’s price. Each narrative links a fair value to a clear story about CME Group's potential catalysts and risks, so you can track over time which version of events is actually unfolding on the Community page.

If you have a number driven view on whether CME Group's record Henry Hub natural gas open interest, broad based volume in futures and options, and new product launches earn the current valuation, share a Narrative and put your case on the record. You can be one of the first voices in the Simply Wall St community to set out a clear thesis on CME Group and then track how it stacks up as new volumes, contracts and regulatory developments emerge.

Do you think there's more to the story for CME Group? Head over to our Community to see what others are saying!

The Bottom Line

For CME Group, the Excess Returns intrinsic value estimate sits close to the market price, which suggests the stock is no longer obviously cheap after its recent run. The P/E view still flags CME Group as overvalued, so the broader checks lean cautious rather than supportive of a clear value opportunity. The crux for investors is whether current trading volumes, product launches and competitive position can sustain the premium that the market is already pricing in, or whether expectations eventually cool and bring the multiple closer to the intrinsic value estimate.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com